sorafenib has been researched along with Neoplasms, Vascular in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bae, SH; Cho, EY; Jang, BK; Jang, JY; Kim, BH; Kim, DY; Kim, HJ; Kim, IH; Kim, JH; Kim, KM; Kim, YJ; Lee, BS; Lee, HW; Lee, JI; Paik, YH; Seo, YS; Sinn, DH; Suh, KS; Yim, HJ | 1 |
| Chen, CH; Chen, YY; Cheng, JY; Cheng, YF; Hu, TH; Lin, CC; Liu, YW; Wang, JH; Yen, YH; Yong, CC | 1 |
| Borden, E; Bramwell, V; Demetri, GD; Goldblum, JR; Rankin, C; Ryan, CW; von Mehren, M | 1 |
1 trial(s) available for sorafenib and Neoplasms, Vascular
| Article | Year |
|---|---|
Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Female; Humans; Leiomyosarcoma; Liposarcoma; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sarcoma; Sorafenib; Survival Rate; Vascular Neoplasms | 2012 |
2 other study(ies) available for sorafenib and Neoplasms, Vascular
| Article | Year |
|---|---|
Patterns and Outcomes in Hepatocellular Carcinoma Patients with Portal Vein Invasion: A Multicenter Prospective Cohort Study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cohort Studies; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Portal Vein; Prospective Studies; Sorafenib; Survival Rate; Treatment Outcome; Vascular Neoplasms | 2021 |
Real world clinical practice in treating advanced hepatocellular carcinoma: When East meets West.
Topics: Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Hepatitis B Surface Antigens; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Risk Factors; Sorafenib; Survival Analysis; Vascular Neoplasms | 2020 |